We also conjugated to an antibody we previously raised against the N-terminal of the calreticulin protein, a biomarker expressed by colorectal and breast cancer cells, to produce targeted NCs (anti-CRT-AuNCs), and demonstrated their binding to cancer cell lines in 2D [16]. This evidence concerns the gene CALR and breast carcinoma.